Anand V Germanwala

Dr. Anand V Germanwala

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
DLDaphne Li
Daphne Li
ATAsterios Tsimpas
Asterios Tsimpas
AGAnand V Germanwala
Anand V Germanwala

1 March 2011 in Operative Neurosurgery
Verified
Journal Article
Closed access
AGAnand V Germanwala
Anand V Germanwala
AZAdam M Zanation
Adam M Zanation
We present a case in which clip ligation of both a ruptured and an unruptured paraclinoidal segment aneurysm is performed with only the endoscopic endonasal approach in 1 setting. A 42-year-old woman, a Hunt and Hess grade 2 patient, presented with aneurysmal subarachnoid hemorrhage. An arteriogram revealed an irregular 10-mm right paraclinoidal aneurysm projecting posteromedially and a 5-mm wide-necked right ophthalmic artery aneurysm projecting superomedially. The patient was taken to the operating room where clipping of both aneurysms was performed through the use of an endonasal endoscopic approach with a pedicled nasoseptal flap reconstruction. Such an approach allowed excellent visualization without drilling of the clinoid process or mobilization of the optic nerve and potential control of the proximal and distal internal carotid artery. An intraoperative arteriogram showed obliteration of both aneurysms with patency of the surrounding vasculature. The patient did well postoperatively and was subsequently discharged home without any neurological deficits. An endoscopic endonasal approach was immediately safe and effective for the clipping of both paraclinoidal aneurysms. Although there were benefits achieved from this particular unconventional approach, surgical clipping via traditional craniotomy and endovascular coiling are the established methods of aneurysm treatment and should always be primarily considered. More cases will determine the efficacy and safety of this approach, which should be attempted only by very experienced teams trained in both cerebrovascular and endonasal neurosurgery.

1 March 2016 in Clinical Neuropathology
Verified
Journal Article
Closed access
BMBlake K. Montgomery
Blake K. Montgomery
MAMeghna Alimchandani
Meghna Alimchandani
GMGautam U. Mehta
Gautam U. Mehta
RDRamita Dewan
Ramita Dewan
CNCody L. Nesvick
Cody L. Nesvick
AGAnand V Germanwala
Anand V Germanwala
Although schwannoma and neurofibroma tumors are generally reported as distinct pathologic diagnoses, sporadic schwannoma/neurofibroma hybrid nerve sheath tumors have been reported in the general population with components of both entities. We report the clinicopathological features of these hybrid nerve sheath tumors in patients with neurofibromatosis type 2 (NF2). A retrospective review of nerve sheath tumor surgical specimens from patients with NF2 enrolled at the National Institutes of Health was performed. Those specimens reported to have schwannoma-like and neurofibromalike features were selected for further characterization by morphology, immunohistochemical panel (CD34, S100, neurofilament triplet protein (immunostain) (NFTP), epithelial membrane antigen (EMA)), and confirmation as hybrid tumors. Of 43 total NF2 patients undergoing resection of nerve sheath tumors, 11 specimens from 11 (26%) patients were found to be benign nerve sheath tumors exhibiting hybrid features of both neurofibroma and schwannoma. Immunohistochemical studies showed the schwannoma component to be S100+, CD 34- while the neurofibroma component was CD34+, variable S100+. Our experience emphasizes the importance of including this distinct tumor subtype, the schwannoma/neurofibroma hybrid tumor, in the differential diagnosis of nerve sheath tumors in NF2 patients and suggests that the relationship between neurofibroma and schwannoma tumors is closer than previously suspected..

1 July 2015 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
DHDaniel M. Heiferman
Daniel M. Heiferman
ASAravind Somasundaram
Aravind Somasundaram
AAAlexis J. Alvarado
Alexis J. Alvarado
AZAdam M. Zanation
Adam M. Zanation
APAmy L. Pittman
Amy L. Pittman
AGAnand V Germanwala
Anand V Germanwala

30 April 2024 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
FBFaraz Behzadi
Faraz Behzadi
DLDiego D. Luy
Diego D. Luy
PSPeter A. Schaible
Peter A. Schaible
JZJoseph F. Zywiciel
Joseph F. Zywiciel
APAva M. Puccio
Ava M. Puccio
AGAnand V Germanwala
Anand V Germanwala

13 February 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NPNisc Comparative Sequencing Program
Nisc Comparative Sequencing Program
RDRamita Dewan
Ramita Dewan
APAlexander Pemov
Alexander Pemov
ADAmalia S. Dutra
Amalia S. Dutra
EPEvgenia D. Pak
Evgenia D. Pak
AGAnand V Germanwala
Anand V Germanwala
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant nervous system tumor predisposition disorder caused by constitutive inactivation of one of the two copies of NF2. Meningiomas affect about one half of NF2 patients, and are associated with a higher disease burden. Currently, the somatic mutation landscape in NF2-associated meningiomas remains largely unexamined. Here, we present an in-depth genomic study of benign and atypical meningiomas, both from a single NF2 patient. While the grade I tumor was asymptomatic, the grade II tumor exhibited an unusually high growth rate: expanding to 335 times its initial volume within one year. The genomes of both tumors were examined by whole-exome sequencing (WES) complemented with spectral karyotyping (SKY) and SNP-array copy-number analyses. To better understand the clonal composition of the atypical meningioma, the tumor was divided in four sections and each section was investigated independently. Both tumors had second copy inactivation of NF2, confirming the central role of the gene in meningioma formation. The genome of the benign tumor closely resembled that of a normal diploid cell and had only one other deleterious mutation (EPHB3). In contrast, the chromosomal architecture of the grade II tumor was highly re-arranged, yet uniform among all analyzed fragments, implying that this large and fast growing tumor was composed of relatively few clones. Besides multiple gains and losses, the grade II meningioma harbored numerous chromosomal translocations. WES analysis of the atypical tumor identified deleterious mutations in two genes: ADAMTSL3 and CAPN5 in all fragments, indicating that the mutations were present in the cell undergoing fast clonal expansion This is the first WES study of NF2-associated meningiomas. Besides second NF2 copy inactivation, we found low somatic burden in both tumors and high level of genomic instability in the atypical meningioma. Genomic instability resulting in altered gene dosage and compromised structural integrity of multiple genes may be the primary reason of the high growth rate for the grade II tumor. Further study of ADAMTSL3 and CAPN5 may lead to elucidation of their molecular implications in meningioma pathogenesis.